{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:45:03Z","timestamp":1789181103344,"version":"build-2803163510"},"reference-count":385,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004100","name":"Labex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004100","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2019.00268","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T04:24:49Z","timestamp":1574828689000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience"],"prefix":"10.3389","volume":"6","author":[{"given":"Marie","family":"Beaurain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Salabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Joao","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Arlicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Damier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Le Jeune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Demonet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Payoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"key":"B1","first-page":"18N","article-title":"A definition of molecular imaging","volume":"48","author":"Mankoff","year":"2007","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.crad.2010.03.011","article-title":"Molecular imaging: current status and emerging strategies","volume":"65","author":"Pysz","year":"2010","journal-title":"Clin Radiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1212\/WNL.50.2.445","article-title":"Subtraction ictal SPECT co-registered to MRI improves clinical usefulness of SPECT in localizing the surgical seizure focus","volume":"50","author":"O'Brien","year":"1998","journal-title":"Neurology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00259-009-1264-0","article-title":"EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2","volume":"36","author":"Varrone","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/mds.27323","article-title":"Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment","volume":"33","author":"Goldman","year":"2018","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1007\/s00213-015-3938-6","article-title":"Application of cross-species PET imaging to assess neurotransmitter release in brain","volume":"232","author":"Finnema","year":"2015","journal-title":"Psychopharmacology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.mednuc.2008.02.001","article-title":"Imagerie mol\u00e9culaire de la maladie de Parkinson : donn\u00e9es actuelles","volume":"32","author":"Baulieu","year":"2008","journal-title":"M\u00e9decine Nucl."},{"key":"B9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/305137a0","article-title":"Dopamine visualized in the basal ganglia of living man","volume":"305","author":"Garnett","year":"1983","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"iii40","DOI":"10.1007\/s00415-002-1309-9","article-title":"Early diagnosis of Parkinson's disease","volume":"249","author":"Becker","year":"2002","journal-title":"J Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/ana.410340304","article-title":"Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels","volume":"34","author":"Snow","year":"1993","journal-title":"Ann Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s002590050566","article-title":"Comparison of clinical data sets acquired on different tomographs using 6-18F-L-dopa","volume":"27","author":"Ribeiro","year":"2000","journal-title":"Eur J Nucl Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2967\/jnumed.109.066811","article-title":"Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes","volume":"51","author":"Ma","year":"2010","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s12149-016-1143-2","article-title":"A revisit to quantitative PET with 18F-FDOPA of high specific activity using a high-resolution condition in view of application to regenerative therapy","volume":"31","author":"Akamatsu","year":"2017","journal-title":"Ann Nucl Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2967\/jnumed.110.078337","article-title":"Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I","volume":"51","author":"Ziebell","year":"2010","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/(SICI)1098-2396(19990301)31:3<178::AID-SYN2>3.0.CO;2-M","article-title":"Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models","volume":"31","author":"Ito","year":"1999","journal-title":"Synap N Y N"},{"key":"B17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s00259-005-1904-y","article-title":"Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease","volume":"33","author":"Eshuis","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study","volume":"6","author":"McKeith","year":"2007","journal-title":"Lancet Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00213-006-0570-5","article-title":"Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait","volume":"191","author":"Mateos","year":"2007","journal-title":"Psychopharmacology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pnpbp.2007.08.013","article-title":"Changes in midbrain serotonin transporter availability in atypically depressed subjects after one year of psychotherapy","volume":"32","author":"Lehto","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B21","first-page":"999","article-title":"Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients","volume":"44","author":"Huang","year":"2003","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B22","first-page":"584","article-title":"Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers","volume":"41","author":"Mozley","year":"2000","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/BF00881808","article-title":"[99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent","volume":"24","author":"Kung","year":"1997","journal-title":"Eur J Nucl Med."},{"key":"B24","first-page":"1303","article-title":"Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging","volume":"42","author":"Huang","year":"2001","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1755-5949.2007.00033.x","article-title":"PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter","volume":"14","author":"Emond","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1124\/jpet.105.096792","article-title":"Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter","volume":"317","author":"Chalon","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bmc.2005.09.035","article-title":"Synthesis, radiosynthesis and in vivo preliminary evaluation of [11C]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET","volume":"14","author":"Doll\u00e9","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/syn.20337","article-title":"[11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET","volume":"61","author":"Saba","year":"2007","journal-title":"Synap N Y N"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2967\/jnumed.111.089953","article-title":"Imaging of the striatal and extrastriatal dopamine transporter with (18)F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates","volume":"52","author":"Varrone","year":"2011","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ncpneuro0773","article-title":"Technology insight: imaging neurodegeneration in Parkinson's disease","volume":"4","author":"Brooks","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11910-018-0830-x","article-title":"New imaging markers for movement disorders","volume":"18","author":"Ghadery","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/syn.20653","article-title":"Visualizing vesicular dopamine dynamics in Parkinson's disease","volume":"63","author":"Fuente-Fern\u00e1ndez R de","year":"2009","journal-title":"Synapse."},{"key":"B33","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00702-004-0208-x","article-title":"Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients","volume":"112","author":"Plotkin","year":"2005","journal-title":"J Neural Transm"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s00259-004-1578-x","article-title":"Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy","volume":"31","author":"Knudsen","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B35","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.parkreldis.2012.01.009","article-title":"123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis","volume":"18","author":"Orimo","year":"2012","journal-title":"Parkinsonism Relat Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.neuropharm.2008.05.022","article-title":"Imaging dopamine's role in drug abuse and addiction","volume":"56","author":"Volkow","year":"2009","journal-title":"Neuropharmacology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"259349","DOI":"10.1155\/2012\/259349","article-title":"Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders","volume":"2012","author":"Shen","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1212\/WNL.0b013e3181d55f61","article-title":"Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo","volume":"74","author":"Klein","year":"2010","journal-title":"Neurology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1212\/WNL.55.10.1575","article-title":"18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies","volume":"55","author":"Hu","year":"2000","journal-title":"Neurology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.nbd.2011.12.053","article-title":"Brain monoamine systems in multiple system atrophy: a positron emission tomography study","volume":"46","author":"Lewis","year":"2012","journal-title":"Neurobiol Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00702-006-0536-0","article-title":"Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an 18F-dopa PET study","volume":"114","author":"Tai","year":"2007","journal-title":"J Neural Transm"},{"key":"B42","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0969-8051(97)00101-7","article-title":"In vivo radiotracers for vesicular neurotransmitter transporters","volume":"24","author":"Kilbourn","year":"1997","journal-title":"Nucl Med Biol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ana.21320","article-title":"Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease","volume":"63","author":"Martin","year":"2008","journal-title":"Ann Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jalz.2007.11.016","article-title":"Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography","volume":"4","author":"Koeppe","year":"2008","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"key":"B45","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/ana.20088","article-title":"Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease","volume":"55","author":"Gilman","year":"2004","journal-title":"Ann Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1212\/01.WNL.0000073624.13436.32","article-title":"Obstructive sleep apnea is related to a thalamic cholinergic deficit in MSA","volume":"61","author":"Gilman","year":"2003","journal-title":"Neurology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1212\/01.WNL.0000073745.68744.94","article-title":"REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA","volume":"61","author":"Gilman","year":"2003","journal-title":"Neurology."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1021\/jm960795d","article-title":"Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter","volume":"40","author":"Emond","year":"1997","journal-title":"J Med Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1212\/WNL.0000000000000960","article-title":"Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study","volume":"83","author":"Jennings","year":"2014","journal-title":"Neurology."},{"key":"B50","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1002\/ana.410440725","article-title":"Dopamine agonists and neuroprotection in Parkinson's disease","volume":"44","author":"Olanow","year":"1998","journal-title":"Ann Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","article-title":"Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression","volume":"287","year":"2002","journal-title":"JAMA"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N Engl J Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2967\/jnumed.109.065870","article-title":"The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies","volume":"50","author":"Lim","year":"2009","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.nucmedbio.2010.01.002","article-title":"Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats","volume":"37","author":"Tsao","year":"2010","journal-title":"Nucl Med Biol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamaneurol.2014.290","article-title":"Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography","volume":"71","author":"Hsiao","year":"2014","journal-title":"JAMA Neurol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/archneurol.2011.142","article-title":"In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease","volume":"68","author":"Villemagne","year":"2011","journal-title":"Arch Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5665\/sleep.5452","article-title":"A four-year longitudinal study on restless legs syndrome in Parkinson Disease","volume":"39","author":"Moccia","year":"2016","journal-title":"Sleep"},{"key":"B58","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/01.mnm.0000202858.45522.df","article-title":"123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study","volume":"27","author":"Filippi","year":"2006","journal-title":"Nucl Med Commun."},{"key":"B59","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/jnnp.62.2.133","article-title":"[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease","volume":"62","author":"Booij","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B60","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1192\/bjp.bp.114.148643","article-title":"Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study","volume":"206","author":"Walker","year":"2015","journal-title":"Br J Psychiatry J Ment Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00259-005-1920-y","article-title":"Quantitative simultaneous (99m)Tc-ECD\/123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy","volume":"33","author":"El Fakhri","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/0024-3205(88)90123-3","article-title":"In vitro binding properties and autoradiographic imaging of 3-iodobenzamide ([125I]-IBZM): A potential imaging ligand for D-2 dopamine receptors in spect","volume":"42","author":"Br\u00fccke","year":"1988","journal-title":"Life Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/archneur.1993.00540050063017","article-title":"Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography","volume":"50","author":"van Royen","year":"1993","journal-title":"Arch Neurol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/mds.20229","article-title":"Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease","volume":"19","author":"Seppi","year":"2004","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"B65","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-3-7091-6641-3_9","article-title":"Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI","volume":"42","author":"Arnold","year":"1994","journal-title":"J Neural Transm Suppl"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00259-004-1480-6","article-title":"Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1","volume":"31","author":"Van Laere","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B67","first-page":"648","article-title":"The characterization of IBF as a new selective dopamine D-2 receptor imaging agent","volume":"31","author":"Kung","year":"1990","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/mds.10042","article-title":"Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP","volume":"17","author":"Kim","year":"2002","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"B69","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1552-6569.2002.tb00139.x","article-title":"Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography","volume":"12","author":"Oyanagi","year":"2002","journal-title":"J Neuroimaging Off J Am Soc Neuroimaging"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.2967\/jnumed.115.171231","article-title":"Optimal acquisition time window and simplified quantification of dopamine transporter availability using 18F-FE-PE2I in healthy controls and Parkinson disease patients","volume":"57","author":"Sonni","year":"2016","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B71","first-page":"663","article-title":"Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease","volume":"44","author":"Prunier","year":"2003","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.2967\/jnumed.112.114025","article-title":"Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies","volume":"54","author":"Ziebell","year":"2013","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/mds.21573","article-title":"Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy","volume":"22","author":"Warren","year":"2007","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"B74","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-3-642-74430-3_13","article-title":"Animal pharmacology of raclopride, a selective dopamine D2 antagonist","volume":"7","author":"Hall","year":"1989","journal-title":"Psychopharmacol Ser"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/brain\/120.12.2187","article-title":"Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease","volume":"120","author":"Antonini","year":"1997","journal-title":"Brain J Neurol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"588","DOI":"10.2967\/jnumed.109.070144","article-title":"Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease","volume":"51","author":"Van Laere","year":"2010","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.nucmedbio.2013.09.007","article-title":"In vivo PET quantification of the dopamine transporter in rat brain with [18F]LBT-999","volume":"41","author":"S\u00e9rri\u00e8re","year":"2014","journal-title":"Nucl Med Biol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/0024-3205(96)00348-7","article-title":"18F-desmethoxyfallypride: A fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for pet imaging studies of dopamine D2 receptors","volume":"59","author":"Mukherjee","year":"1996","journal-title":"Life Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/j.1528-1167.2006.00561.x","article-title":"Decreased dopamine D2\/D3-receptor binding in temporal lobe epilepsy: an [18F]fallypride PET study","volume":"47","author":"Werhahn","year":"2006","journal-title":"Epilepsia."},{"key":"B80","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.semnuclmed.2012.07.001","article-title":"Development of positron emission tomography \u03b2-amyloid plaque imaging agents","volume":"42","author":"Mathis","year":"2012","journal-title":"Semin Nucl Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1001\/archneur.64.3.431","article-title":"Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report","volume":"64","author":"Bacskai","year":"2007","journal-title":"Arch Neurol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3233\/JAD-2010-100222","article-title":"Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging","volume":"21","author":"Hatashita","year":"2010","journal-title":"J Alzheimers Dis JAD."},{"key":"B85","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann Neurol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ana.21955","article-title":"Relationship between atrophy and beta-amyloid deposition in Alzheimer disease","volume":"67","author":"Ch\u00e9telat","year":"2010","journal-title":"Ann Neurol."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm238","article-title":"Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease","author":"Pike","year":"2007","journal-title":"Brain J Neurol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/WCO.0000000000000489","article-title":"New PET markers for the diagnosis of dementia","volume":"30","author":"Payoux","year":"2017","journal-title":"Curr Opin Neurol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"902","DOI":"10.2967\/jnumed.111.099606","article-title":"Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls","volume":"53","author":"Newberg","year":"2012","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B90","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1212\/WNL.0000000000002235","article-title":"Relationship of regional brain \u03b2-amyloid to gait speed","volume":"86","author":"Del Campo","year":"2016","journal-title":"Neurology."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1097\/RLU.0000000000000666","article-title":"18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease","volume":"40","author":"Bailly","year":"2015","journal-title":"Clin Nucl Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.114.147454","article-title":"18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease","volume":"56","author":"Kobylecki","year":"2015","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1358\/dot.2014.050.03.2116672","article-title":"Flutemetamol (18F): a \u03b2-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis","volume":"50","author":"de Lartigue","year":"2014","journal-title":"Drugs Today"},{"key":"B94","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jalz.2012.01.006","article-title":"Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease","volume":"9","author":"Duara","year":"2013","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"B95","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00259-015-3228-x","article-title":"Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"43","author":"Morris","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1007\/s00259-011-1821-1","article-title":"Individualized quantification of brain \u03b2-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls","volume":"38","author":"Barthel","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B97","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2174\/1567205013666160620114309","article-title":"Usefulness of 18F florbetaben in diagnosis of Alzheimer's disease and other types of dementia","volume":"14","author":"Chiaravalloti","year":"2017","journal-title":"Curr Alzheimer Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"key":"B99","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/jnnp-2014-308094","article-title":"A\u03b2 imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study","volume":"86","author":"Ong","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1212\/WNL.56.9.1143","article-title":"Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"56","author":"Knopman","year":"2001","journal-title":"Neurology."},{"key":"B101","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.dadm.2014.11.004","article-title":"A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease","volume":"1","author":"Yeo","year":"2015","journal-title":"Alzheimers Dement Amst Neth"},{"key":"B102","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/brain\/awp326","article-title":"Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden","volume":"133","author":"Rabinovici","year":"2010","journal-title":"Brain J Neurol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/brain\/aws327","article-title":"Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease","volume":"136","author":"Lehmann","year":"2013","journal-title":"Brain J Neurol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/ene.12761","article-title":"Regional \u03b2-amyloid burden does not correlate with cognitive or language deficits in Alzheimer's disease presenting as aphasia","volume":"23","author":"Jung","year":"2016","journal-title":"Eur J Neurol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.jalz.2018.06.2855","article-title":"Molecular imaging in dementia: Past, present, and future","volume":"14","author":"Laforce","year":"2018","journal-title":"Alzheimers Dement"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e-1-16","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"key":"B107","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.14506.1","article-title":"Current understanding of Alzheimer's disease diagnosis and treatment","volume":"7","author":"Weller","year":"2018","journal-title":"F1000Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.neurol.2014.10.003","article-title":"Amyloid beta peptide immunotherapy in Alzheimer disease","volume":"170","author":"Delrieu","year":"2014","journal-title":"Rev Neurol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.arr.2017.03.002","article-title":"In vivo tau PET imaging in dementia: pathophysiology, radiotracer quantification, and a systematic review of clinical findings","volume":"36","author":"Hall","year":"2017","journal-title":"Ageing Res Rev."},{"key":"B111","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.410410106","article-title":"Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease","volume":"41","author":"G\u00f3mez-Isla","year":"1997","journal-title":"Ann Neurol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3233\/JAD-2011-111694","article-title":"Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease","volume":"29","author":"van Rossum","year":"2012","journal-title":"J Alzheimers Dis JAD."},{"key":"B113","doi-asserted-by":"publisher","first-page":"RC189","DOI":"10.1523\/JNEUROSCI.21-24-j0004.2001","article-title":"Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease","volume":"21","author":"Agdeppa","year":"2001","journal-title":"J Neurosci Off J Soc Neurosci."},{"key":"B114","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.nucmedbio.2008.09.002","article-title":"Peripheral metabolism of [(18)F]FDDNP and cerebral uptake of its labelled metabolites","volume":"35","author":"Luurtsema","year":"2008","journal-title":"Nucl Med Biol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"10857","DOI":"10.1523\/JNEUROSCI.1738-05.2005","article-title":"Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease","volume":"25","author":"Okamura","year":"2005","journal-title":"J Neurosci Off J Soc Neurosci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awr038","article-title":"18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease","volume":"134","author":"Fodero-Tavoletti","year":"2011","journal-title":"Brain J Neurol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/alzrt240","article-title":"Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies","volume":"6","author":"Fodero-Tavoletti","year":"2014","journal-title":"Alzheimers Res Ther."},{"key":"B118","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00259-013-2681-7","article-title":"In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease","volume":"41","author":"Villemagne","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B119","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2967\/jnumed.115.164848","article-title":"18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease","volume":"57","author":"Harada","year":"2016","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/JAD-122059","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807","volume":"34","author":"Chien","year":"2013","journal-title":"J Alzheimers Dis JAD."},{"key":"B121","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/JAD-130098","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808","volume":"38","author":"Chien","year":"2014","journal-title":"J Alzheimers Dis JAD."},{"key":"B122","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer disease","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann Neurol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer's disease","volume":"8","author":"Brier","year":"2016","journal-title":"Sci Transl Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1212\/WNL.0000000000003050","article-title":"Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly","volume":"87","author":"Chhatwal","year":"2016","journal-title":"Neurology."},{"key":"B125","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of AV-1451 Tau PET in dementia","volume":"4","author":"Lowe","year":"2016","journal-title":"Acta Neuropathol Commun."},{"key":"B126","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1021\/acs.jmedchem.6b00166","article-title":"Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): a Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs)","volume":"59","author":"Walji","year":"2016","journal-title":"J Med Chem."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","article-title":"Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles","volume":"57","author":"Hostetler","year":"2016","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B128","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2967\/jnumed.118.208215","article-title":"First-in-human brain imaging of Alzheimer dementia patients and elderly controls with 18F-MK-6240, a PET tracer targeting neurofibrillary tangle pathology","volume":"60","author":"Lohith","year":"2019","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1161\/ATVBAHA.114.305067","article-title":"64Cu-DOTATATE PET\/MRI for detection of activated macrophages in carotid atherosclerotic plaques","volume":"35","author":"Pedersen","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s13311-016-0490-y","article-title":"Tau imaging in alzheimer's disease diagnosis and clinical trials","volume":"14","author":"Brosch","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B131","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2174\/1567205011310030001","article-title":"Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies","volume":"10","author":"Rosenmann","year":"2013","journal-title":"Curr Alzheimer Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"Lancet Neurol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2217\/imt-2016-0019","article-title":"Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy","volume":"8","author":"Panza","year":"2016","journal-title":"Immunotherapy"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.2967\/jnumed.116.182881","article-title":"Kinetic modeling of the Tau PET tracer 18F-AV-1451 in human healthy volunteers and Alzheimer disease subjects","volume":"58","author":"Barret","year":"2017","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","article-title":"Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease","volume":"157","author":"Maass","year":"2017","journal-title":"NeuroImage"},{"key":"B136","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awx243","article-title":"Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease","volume":"140","author":"Bejanin","year":"2017","journal-title":"Brain J Neurol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","article-title":"Discriminative accuracy of [18F]flortaucipir positron emission tomography for alzheimer disease vs other neurodegenerative disorders","volume":"320","author":"Ossenkoppele","year":"2018","journal-title":"JAMA"},{"key":"B138","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3233\/JAD-2012-120712","article-title":"A highly selective and specific PET tracer for imaging of tau pathologies","volume":"31","author":"Zhang","year":"2012","journal-title":"J Alzheimers Dis JAD."},{"key":"B139","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s13139-015-0374-9","article-title":"PET radioligands for imaging of tau pathology: current status","volume":"49","author":"Choe","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s00259-015-3035-4","article-title":"[(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease","volume":"42","author":"Harada","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.2967\/jnumed.112.117341","article-title":"Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease","volume":"54","author":"Okamura","year":"2013","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/brain\/awu064","article-title":"Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET","volume":"137","author":"Okamura","year":"2014","journal-title":"Brain J Neurol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jalz.2016.06.998","article-title":"Association between A\u03b2 and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study","volume":"6","author":"Shimada","year":"2017","journal-title":"Alzheimers Dement Amst Neth."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/mds.27029","article-title":"PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins","volume":"32","author":"Perez-Soriano","year":"2017","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"B145","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1212\/WNL.0000000000006736","article-title":"Tau imaging detects distinctive distribution of tau pathology in ALS\/PDC on the Kii Peninsula","volume":"92","author":"Shinotoh","year":"2019","journal-title":"Neurology."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1536012118792317","DOI":"10.1177\/1536012118792317","article-title":"Emerging PET radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: outlook beyond TSPO","volume":"17","author":"Narayanaswami","year":"2018","journal-title":"Mol Imaging"},{"key":"B147","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2967\/jnumed.114.141713","article-title":"Imaging microglial activation with TSPO PET: lighting up neurologic diseases?","volume":"57","author":"Vivash","year":"2016","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B148","doi-asserted-by":"publisher","first-page":"E785","DOI":"10.3390\/ijms18040785","article-title":"Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) imaging and its clinical impact in neurodegenerative diseases","volume":"18","author":"Dupont","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.2967\/jnumed.115.169078","article-title":"Flutriciclamide (18F-GE180) PET: first-in-human PET study of novel third-generation in vivo marker of human translocator protein","volume":"57","author":"Fan","year":"2016","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B150","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2967\/jnumed.116.178996","article-title":"11C-ER176, a radioligand for 18-kDa translocator protein, has adequate sensitivity to robustly image all three affinity genotypes in human brain","volume":"58","author":"Ikawa","year":"2017","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00259-015-3047-0","article-title":"Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study","volume":"42","author":"Rodriguez-Vieitez","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B152","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.2967\/jnumed.110.084046","article-title":"In vivo expression of cyclooxygenase-1 in activated microglia and macrophages during neuroinflammation visualized by PET with 11C-ketoprofen methyl ester","volume":"52","author":"Shukuri","year":"2011","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B153","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.nucmedbio.2016.04.005","article-title":"Exploratory human PET study of the effectiveness of (11)C-ketoprofen methyl ester, a potential biomarker of neuroinflammatory processes in Alzheimer's disease","volume":"43","author":"Ohnishi","year":"2016","journal-title":"Nucl Med Biol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jacbts.2018.02.003","article-title":"In vivo reactive oxygen species detection with a novel positron emission tomography tracer, 18F-DHMT, allows for early detection of anthracycline-induced cardiotoxicity in rodents","volume":"3","author":"Boutagy","year":"2018","journal-title":"JACC Basic Transl Sci."},{"key":"B155","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1021\/acschemneuro.7b00385","article-title":"Development of a positron emission tomography radiotracer for imaging elevated levels of superoxide in neuroinflammation","volume":"9","author":"Hou","year":"2018","journal-title":"ACS Chem Neurosci."},{"key":"B156","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s13139-017-0475-8","article-title":"Recent progress in the development of TSPO PET ligands for neuroinflammation imaging in neurological diseases","volume":"51","author":"Alam","year":"2017","journal-title":"Nucl Med Mol Imaging"},{"key":"B157","doi-asserted-by":"publisher","first-page":"e1989","DOI":"10.1212\/WNL.0000000000005610","article-title":"[11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy","volume":"90","author":"Passamonti","year":"2018","journal-title":"Neurology."},{"key":"B158","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.nbd.2008.08.001","article-title":"Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study","volume":"32","author":"Edison","year":"2008","journal-title":"Neurobiol Dis."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/brain\/aww017","article-title":"Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging","volume":"139","author":"Hamelin","year":"2016","journal-title":"Brain J Neurol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/jcbfm.2014.261","article-title":"Quantification of [18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimer's disease patients","volume":"35","author":"Golla","year":"2015","journal-title":"J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab."},{"key":"B161","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00259-013-2359-1","article-title":"In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients","volume":"40","author":"Varrone","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B162","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/2191-219X-3-30","article-title":"In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106","volume":"3","author":"Takano","year":"2013","journal-title":"EJNMMI Res"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.bmcl.2011.12.084","article-title":"[18F]GE-180: a novel fluorine-18 labelled PET tracer for imaging Translocator protein 18 kDa (TSPO)","volume":"22","author":"Wadsworth","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"B164","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13550-017-0340-x","article-title":"TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis","volume":"7","author":"Vomacka","year":"2017","journal-title":"EJNMMI Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/mp.2015.1","article-title":"In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA","volume":"20","author":"Suridjan","year":"2015","journal-title":"Mol Psychiatry."},{"key":"B166","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/brain\/awv404","article-title":"Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease","volume":"139","author":"Rodriguez-Vieitez","year":"2016","journal-title":"Brain J Neurol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1097\/RLU.0000000000002179","article-title":"18F-PBR06 versus 11C-PBR28 PET for assessing white matter translocator protein binding in multiple sclerosis","volume":"43","author":"Singhal","year":"2018","journal-title":"Clin Nucl Med."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.2967\/jnumed.113.135129","article-title":"In vivo assessment of brain white matter inflammation in multiple sclerosis with (18)F-PBR111 PET","volume":"55","author":"Colasanti","year":"2014","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2967\/jnumed.117.203315","article-title":"18F-PBR111 PET imaging in healthy controls and schizophrenia: test-retest reproducibility and quantification of neuroinflammation","volume":"59","author":"Ottoy","year":"2018","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B170","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.nbd.2015.09.004","article-title":"Brain inflammation in a chronic epilepsy model: Evolving pattern of the translocator protein during epileptogenesis","volume":"82","author":"Amhaoul","year":"2015","journal-title":"Neurobiol Dis."},{"key":"B171","doi-asserted-by":"publisher","first-page":"716514","DOI":"10.1155\/2015\/716514","article-title":"Development of PET and SPECT probes for glutamate receptors","volume":"2015","author":"Fuchigami","year":"2015","journal-title":"ScientificWorldJournal"},{"key":"B172","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1196\/annals.1300.027","article-title":"Evaluation of NMDA receptors in vivo in schizophrenic patients with [123I]CNS 1261 and SPET: preliminary findings","volume":"1003","author":"Bressan","year":"2003","journal-title":"Ann N Y Acad Sci."},{"key":"B173","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.biopsych.2005.03.016","article-title":"Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo","volume":"58","author":"Bressan","year":"2005","journal-title":"Biol Psychiatry."},{"key":"B174","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2967\/jnumed.115.162461","article-title":"The PET radioligand 18F-FIMX images and quantifies metabotropic glutamate receptor 1 in proportion to the regional density of its gene transcript in human brain","volume":"57","author":"Zanotti-Fregonara","year":"2016","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B175","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.neuroimage.2010.04.164","article-title":"Quantitation of glutamate mGluR5 receptor with 18F-FPEB PET in humans","volume":"51","author":"Barret","year":"2010","journal-title":"J Nucl Med."},{"key":"B176","doi-asserted-by":"publisher","first-page":"682","DOI":"10.2967\/jnumed.117.199422","article-title":"Lower limbic metabotropic glutamate receptor 5 availability in alcohol dependence","volume":"59","author":"Leurquin-Sterk","year":"2018","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B177","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.bpsc.2017.03.019","article-title":"Metabotropic glutamate receptor 5 and glutamate involvement in major depressive disorder: a multimodal imaging study","volume":"2","author":"Abdallah","year":"2017","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging."},{"key":"B178","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40673-018-0082-1","article-title":"Metabotropic glutamate receptor 5 tracer [18F]-FPEB displays increased binding potential in postcentral gyrus and cerebellum of male individuals with autism: a pilot PET study","volume":"5","author":"Fatemi","year":"2018","journal-title":"Cerebellum Ataxias."},{"key":"B179","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nucmedbio.2015.04.001","article-title":"Radiolabeling of [18F]-fluoroethylnormemantine and initial in vivo evaluation of this innovative PET tracer for imaging the PCP sites of NMDA receptors","volume":"42","author":"Salabert","year":"2015","journal-title":"Nucl Med Biol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.biopsych.2013.06.026","article-title":"Imaging glutamate homeostasis in cocaine addiction with the metabotropic glutamate receptor 5 positron emission tomography radiotracer [(11)C]ABP688 and magnetic resonance spectroscopy","volume":"75","author":"Martinez","year":"2014","journal-title":"Biol Psychiatry"},{"key":"B181","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1176\/appi.ajp.2011.09111607","article-title":"Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study","volume":"168","author":"Deschwanden","year":"2011","journal-title":"Am J Psychiatry"},{"key":"B182","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00429-014-0978-3","article-title":"In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD","volume":"221","author":"Leuzy","year":"2016","journal-title":"Brain Struct Funct"},{"key":"B183","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41398-017-0066-6","article-title":"Metabotropic glutamate receptor 5 binding in male patients with alcohol use disorder","volume":"8","author":"Akkus","year":"2018","journal-title":"Transl Psychiatry."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.2967\/jnumed.113.119891","article-title":"Initial human PET studies of metabotropic glutamate receptor type 1 ligand 11C-ITMM","volume":"54","author":"Toyohara","year":"2013","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B185","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00259-014-2883-7","article-title":"Preclinical evaluation and test-retest studies of [(18)F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5)","volume":"42","author":"Sephton","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00259-017-3879-x","article-title":"A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5","volume":"45","author":"Warnock","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B187","first-page":"355","article-title":"Biodistribution, dosimetry and kinetic modeling of [11C]JNJ-42491293, a PET tracer for the mGluR2 receptor in the human brain","volume":"53","author":"Laere","year":"2012","journal-title":"J Nucl Med."},{"key":"B188","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF02189982","article-title":"Glutamate in the mammalian CNS","volume":"240","author":"Sahai","year":"1990","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1046\/j.1460-9568.1999.00594.x","article-title":"Investigation by ion channel domain transplantation of rat glutamate receptor subunits, orphan receptors and a putative NMDA receptor subunit","volume":"11","author":"Villmann","year":"1999","journal-title":"Eur J Neurosci"},{"key":"B190","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/j.1471-4159.2005.03027.x","article-title":"Kinetics and subunit composition of NMDA receptors in respiratory-related neurons","volume":"93","author":"Paarmann","year":"2005","journal-title":"J Neurochem."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1213\/01.ANE.0000081061.12235.55","article-title":"The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review","volume":"97","author":"Petrenko","year":"2003","journal-title":"Anesth Analg."},{"key":"B192","first-page":"7","article-title":"The glutamate receptor ion channels","volume":"51","author":"Dingledine","year":"1999","journal-title":"Pharmacol Rev"},{"key":"B193","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s002210050399","article-title":"Cooperative interaction among the various regulatory sites within the NMDA receptor-channel complex in modulating the evoked responses to noxious thermal stimuli of spinal dorsal horn neurons in the cat","volume":"120","author":"Song","year":"1998","journal-title":"Exp Brain Res"},{"key":"B194","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1126\/science.284.5421.1845","article-title":"Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein","volume":"284","author":"Sattler","year":"1999","journal-title":"Science"},{"key":"B195","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0165-0173(02)00157-1","article-title":"Cerebral ischemia and trauma-different etiologies yet similar mechanisms: neuroprotective opportunities","volume":"39","author":"Leker","year":"2002","journal-title":"Brain Res Brain Res Rev"},{"key":"B196","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S1474-4422(08)70165-0","article-title":"NMDA receptors in clinical neurology: excitatory times ahead","volume":"7","author":"Kalia","year":"2008","journal-title":"Lancet Neurol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrn2153","article-title":"NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders","volume":"8","author":"Lau","year":"2007","journal-title":"Nat Rev Neurosci."},{"key":"B198","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/jlcr.2580311115","article-title":"Synthesis of 3-[18F]-fluoromethyl-TCP1, A potential tool for pet study of the nmda receptor channel complex","volume":"31","author":"Ponchant","year":"1992","journal-title":"J Label Compd Radiopharm."},{"key":"B199","first-page":"352","article-title":"Synthesis of a new analog of PCP Fluorine-18 3-fluoromethyl-TCP, a potent ligand for the NMDA glutamatergic receptor","volume":"32","author":"Ponchant","year":"1993","journal-title":"J Label Compd Radiopharm."},{"key":"B200","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0969-8051(96)00186-2","article-title":"Carbon-11 labelled ketamine\u2014Synthesis, distribution in mice and PET studies in baboons","volume":"24","author":"Shiue","year":"1997","journal-title":"Nucl Med Biol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0969-8051(01)00293-1","article-title":"PET studies of 18F-memantine in healthy volunteers","volume":"29","author":"Ametamey","year":"2002","journal-title":"Nucl Med Biol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/10799899909036640","article-title":"Fluorine-18 radiolabelling, biodistribution studies and preliminary pet evaluation of a new memantine derivative for imaging the NMDA receptor","volume":"19","author":"Ametamey","year":"1999","journal-title":"J Recept Signal Transduct."},{"key":"B203","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0883-2889(90)90098-2","article-title":"Synthesis of 11C-labeled (\u00b1)-5-methyl-10, 11-dihydro-5H-dibenzo[a,d]cyclohepten-5, 10-imine [(\u00b1)-[11C]MK801]","volume":"41","author":"Kiesewetter","year":"1990","journal-title":"Int J Rad Appl Instrum."},{"key":"B204","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0022-3956(97)00031-9","article-title":"123Iodo-MK-801: a spect agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease","volume":"31","author":"Brown","year":"1997","journal-title":"J Psychiatr Res"},{"key":"B205","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.drudis.2012.10.004","article-title":"PET and SPECT tracers for glutamate receptors","volume":"18","author":"Majo","year":"2013","journal-title":"Drug Discov Today."},{"key":"B206","doi-asserted-by":"publisher","first-page":"870","DOI":"10.2174\/138955710791608299","article-title":"PET and SPECT imaging of the NMDA receptor system: an overview of radiotracer development","volume":"10","author":"Sobrio","year":"2010","journal-title":"Mini Rev Med Chem."},{"key":"B207","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.2174\/138161209788957438","article-title":"Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia","volume":"15","author":"Stone","year":"2009","journal-title":"Curr Pharm Des."},{"key":"B208","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2967\/jnumed.113.130641","article-title":"Initial evaluation of 18F-GE-179, a putative PET Tracer for activated N-methyl D-aspartate receptors","volume":"55","author":"McGinnity","year":"2014","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B209","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.2967\/jnumed.115.167403","article-title":"Ex vivo tracing of NMDA and GABA-A receptors in rat brain after traumatic brain injury using 18F-GE-179 and 18F-GE-194 autoradiography","volume":"57","author":"L\u00f3pez-Pic\u00f3n","year":"2016","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B210","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.nucmedbio.2018.04.002","article-title":"[18F]-GE-179 positron emission tomography (PET) tracer for N-methyl-d-aspartate receptors: One-pot synthesis and preliminary micro-PET study in a rat model of MCAO","volume":"61","author":"Zhou","year":"2018","journal-title":"Nucl Med Biol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1021\/acschemneuro.7b00327","article-title":"In vivo [18F]GE-179 brain signal does not show NMDA-specific modulation with drug challenges in rodents and nonhuman primates","volume":"9","author":"Schoenberger","year":"2018","journal-title":"ACS Chem Neurosci."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.12.003","article-title":"Evaluation of [18F]FNM biodistribution and dosimetry based on whole-body PET imaging of rats","volume":"59","author":"Salabert","year":"2018","journal-title":"Nucl Med Biol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13550-018-0424-2","article-title":"First in human evaluation of [18F]PK-209, a PET ligand for the ion channel binding site of NMDA receptors","volume":"8","author":"van der Aart","year":"2018","journal-title":"EJNMMI Res."},{"key":"B214","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1016\/j.bmc.2004.03.065","article-title":"Radiosynthesis and pharmacological evaluation of [11C]EMD-95885: a high affinity ligand for NR2B-containing NMDA receptors","volume":"12","author":"Roger","year":"2004","journal-title":"Bioorg Med Chem"},{"key":"B215","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.ejmech.2011.03.013","article-title":"Synthesis, evaluation and metabolic studies of radiotracers containing a 4-(4-[18F]-fluorobenzyl)piperidin-1-yl moiety for the PET imaging of NR2B NMDA receptors","volume":"46","author":"Labas","year":"2011","journal-title":"Eur J Med Chem."},{"key":"B216","first-page":"260","article-title":"PET brain kinetics studies of (11)C-ITMM and (11)C-ITDM,radioprobes for metabotropic glutamate receptor type 1, in a nonhuman primate","volume":"4","author":"Yamasaki","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"B217","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00259-015-3301-5","article-title":"Metabotropic glutamate receptor 5 \u2013 a promising target in drug development and neuroimaging","volume":"43","author":"Pillai","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B218","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/j.1530-0277.2006.00145.x","article-title":"Longitudinal brain magnetic resonance imaging study of the alcohol-preferring rat. Part I: adult brain growth","volume":"30","author":"Sullivan","year":"2006","journal-title":"Alcohol Clin Exp Res"},{"key":"B219","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/jcbfm.2012.195","article-title":"Kinetic analysis of the metabotropic glutamate subtype 5 tracer [18F]FPEB in bolus and bolus-plus-constant-infusion studies in humans","volume":"33","author":"Sullivan","year":"2013","journal-title":"J Cereb Blood Flow Metab"},{"key":"B220","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/jon.12563","article-title":"18F-FPEB PET\/CT shows mGluR5 upregulation in Parkinson's disease","volume":"29","author":"Kang","year":"2019","journal-title":"J Neuroimaging Off J Am Soc Neuroimaging"},{"key":"B221","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/adb.12635","article-title":"Effects of alcohol exposure on the glutamatergic system: a combined longitudinal 18 F-FPEB and 1 H-MRS study in rats","volume":"24","author":"de Laat","year":"2018","journal-title":"Addict Biol"},{"key":"B222","doi-asserted-by":"publisher","first-page":"8390","DOI":"10.1073\/pnas.1701749114","article-title":"Altered metabotropic glutamate receptor 5 markers in PTSD: in vivo and postmortem evidence","volume":"114","author":"Holmes","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"key":"B223","first-page":"247","article-title":"Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688","volume":"48","author":"Ametamey","year":"2007","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B224","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.nucmedbio.2010.04.107","article-title":"Evaluation of a bolus\/infusion protocol for 11C-ABP688, a PET tracer for mGluR5","volume":"37","author":"Burger","year":"2010","journal-title":"Nucl Med Biol."},{"key":"B225","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1093\/cercor\/bhw249","article-title":"Metabotropic Glutamate Receptor Type 5 (mGluR5) cortical abnormalities in focal cortical dysplasia identified in vivo with [11C]ABP688 Positron-Emission Tomography (PET) imaging","volume":"26","author":"DuBois","year":"2016","journal-title":"Cereb Cortex N Y N"},{"key":"B226","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.schres.2016.11.008","article-title":"Metabotropic glutamate receptor 5 neuroimaging in schizophrenia","volume":"183","author":"Akkus","year":"2017","journal-title":"Schizophr Res"},{"key":"B227","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.euroneuro.2018.12.001","article-title":"In vivo metabotropic glutamate receptor 5 availability-associated functional connectivity alterations in drug-na\u00efve young adults with major depression","volume":"29","author":"Kim","year":"2018","journal-title":"Eur Neuropsychopharmacol."},{"key":"B228","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/mp.2017.58","article-title":"Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression","volume":"23","author":"Esterlis","year":"2018","journal-title":"Mol Psychiatry"},{"key":"B229","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.biopsych.2014.06.024","article-title":"In vivo ketamine-induced changes in [11C]ABP688 binding to metabotropic glutamate receptor subtype 5","volume":"77","author":"DeLorenzo","year":"2015","journal-title":"Biol Psychiatry."},{"key":"B230","doi-asserted-by":"publisher","first-page":"1536012118788636","DOI":"10.1177\/1536012118788636","article-title":"Acute ketamine infusion in rat does not affect in vivo [11C]ABP688 binding to metabotropic glutamate receptor subtype 5","volume":"17","author":"Kosten","year":"2018","journal-title":"Mol Imaging."},{"key":"B231","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.neuroimage.2018.10.017","article-title":"Imaging glutamate redistribution after acute N-acetylcysteine administration: a simultaneous PET\/MR study","volume":"184","author":"O'Gorman Tuura","year":"2019","journal-title":"NeuroImage"},{"key":"B232","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.3390\/ph11030083","article-title":"Ketamine and ceftriaxone-induced alterations in glutamate levels do not impact the specific binding of metabotropic glutamate receptor subtype 5 radioligand [18F]PSS232 in the rat brain","volume":"11","author":"M\u00fcller Herde","year":"2018","journal-title":"Pharm Basel Switz"},{"key":"B233","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2967\/jnumed.116.176628","article-title":"What we observe in vivo is not always what we see in vitro: development and validation of 11C-JNJ-42491293, a novel radioligand for mGluR2","volume":"58","author":"Leurquin-Sterk","year":"2017","journal-title":"J Nucl Med."},{"key":"B234","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1007\/s00259-016-3349-x","article-title":"Cholinergic imaging in dementia spectrum disorders","volume":"43","author":"Roy","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B235","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0022-510X(77)90073-9","article-title":"Neurotransmitter enzyme abnormalities in senile dementia: choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue","volume":"34","author":"Perry","year":"1977","journal-title":"J Neurol Sci"},{"key":"B236","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.281.15.1401","article-title":"Cholinergic markers in elderly patients with early signs of Alzheimer disease","volume":"281","author":"Davis","year":"1999","journal-title":"JAMA"},{"key":"B237","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1212\/WNL.52.4.691","article-title":"In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease","volume":"52","author":"Kuhl","year":"1999","journal-title":"Neurology."},{"key":"B238","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/1531-8249(199907)46:1<62::AID-ANA10>3.0.CO;2-P","article-title":"Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy","volume":"46","author":"Shinotoh","year":"1999","journal-title":"Ann Neurol."},{"key":"B239","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1001\/archneur.60.12.1745","article-title":"Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study","volume":"60","author":"Bohnen","year":"2003","journal-title":"Arch Neurol."},{"key":"B240","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neulet.2005.01.031","article-title":"Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease","volume":"380","author":"Bohnen","year":"2005","journal-title":"Neurosci Lett"},{"key":"B241","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1212\/01.wnl.0000191154.78131.f6","article-title":"Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways","volume":"65","author":"Hilker","year":"2005","journal-title":"Neurology."},{"key":"B242","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neulet.2006.08.061","article-title":"Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease","volume":"408","author":"Eggers","year":"2006","journal-title":"Neurosci Lett"},{"key":"B243","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/0969-8051(94)90159-7","article-title":"Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivo","volume":"21","author":"Irie","year":"1994","journal-title":"Nucl Med Biol."},{"key":"B244","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1097\/00004647-199910000-00012","article-title":"Kinetic modeling of N-[11C]Methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography tracer for measurement of acetylcholinesterase activity in human brain","volume":"19","author":"Koeppe","year":"1999","journal-title":"J Cereb Blood Flow Metab"},{"key":"B245","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.nicl.2013.07.012","article-title":"[(123)I]-IBVM SPECT imaging of cholinergic systems in multiple system atrophy: a specific alteration of the ponto-thalamic cholinergic pathways (Ch5-Ch6)","volume":"3","author":"Mazere","year":"2013","journal-title":"NeuroImage Clin"},{"key":"B246","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41380-018-0130-5","article-title":"Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV","volume":"24","author":"Nejad-Davarani","year":"2018","journal-title":"Mol Psychiatry"},{"key":"B247","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2967\/jnumed.113.124792","article-title":"In vivo imaging of human cholinergic nerve terminals with (-)-5-(18)F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses","volume":"55","author":"Petrou","year":"2014","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B248","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/BF02257652","article-title":"Decreased uptake and binding of 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography","volume":"2","author":"Nordberg","year":"1990","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"B249","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/00002093-199505000-00006","article-title":"Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains\u2013in vivo assessment using positron emission tomography","volume":"9","author":"Nordberg","year":"1995","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"B250","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00213-006-0447-7","article-title":"PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease","volume":"188","author":"Kadir","year":"2006","journal-title":"Psychopharmacology"},{"key":"B251","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/archneur.63.12.1771","article-title":"Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging","volume":"63","author":"Sabbagh","year":"2006","journal-title":"Arch Neurol."},{"key":"B252","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/jnnp.2006.108209","article-title":"Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography","volume":"78","author":"O'Brien","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B253","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1007\/s00259-007-0701-1","article-title":"Acetylcholine receptors in dementia and mild cognitive impairment","volume":"35","author":"Sabri","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B254","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1093\/brain\/awt195","article-title":"Alterations in \u03b14\u03b22 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology","volume":"136","author":"Okada","year":"2013","journal-title":"Brain J Neurol."},{"key":"B255","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/j.1471-4159.2008.05483.x","article-title":"Role of GSK-3beta activation and alpha7 nAChRs in Abeta(1-42)-induced tau phosphorylation in PC12 cells","volume":"106","author":"Hu","year":"2008","journal-title":"J Neurochem."},{"key":"B256","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.1523\/JNEUROSCI.6159-08.2009","article-title":"Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease","volume":"29","author":"Dziewczapolski","year":"2009","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"B257","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/jnnp.65.2.155","article-title":"Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study","volume":"65","author":"Asahina","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B258","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.neuroimage.2006.07.026","article-title":"In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia","volume":"33","author":"Colloby","year":"2006","journal-title":"NeuroImage"},{"key":"B259","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.neurobiolaging.2007.02.020","article-title":"PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD","volume":"29","author":"Kadir","year":"2008","journal-title":"Neurobiol Aging."},{"key":"B260","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0883-2897(89)90215-8","article-title":"In vitro and ex vivo evaluation of cyclic aminoalkyl benzilates as potential emission tomography ligands for the muscarinic receptor","volume":"16","author":"Otto","year":"1989","journal-title":"Int J Rad Appl Instrum B"},{"key":"B261","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0969-8051(98)00086-9","article-title":"Radiosynthesis and preliminary evaluation of 5-[123\/125I]iodo-3-(2(S)-azetidinylmethoxy)pyridine: a radioligand for nicotinic acetylcholine receptors","volume":"26","author":"Horti","year":"1999","journal-title":"Nucl Med Biol."},{"key":"B262","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00415-006-0473-8","article-title":"Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT","volume":"254","author":"Pakrasi","year":"2007","journal-title":"J Neurol"},{"key":"B263","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1212\/WNL.0b013e3181ab2b58","article-title":"Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET","volume":"73","author":"Shimada","year":"2009","journal-title":"Neurology."},{"key":"B264","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/mp.2017.183","article-title":"Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV","volume":"22","author":"Aghourian","year":"2017","journal-title":"Mol Psychiatry"},{"key":"B265","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/BF03165414","article-title":"Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-N-methyl-4-piperidyl benzilate\u2013comparison with cerebral blood flow and cerebral glucose metabolism","volume":"12","author":"Yoshida","year":"1998","journal-title":"Ann Nucl Med."},{"key":"B266","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1021\/jm980170a","article-title":"2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling","volume":"41","author":"Koren","year":"1998","journal-title":"J Med Chem."},{"key":"B267","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1046\/j.1471-4159.1998.71041750.x","article-title":"In vitro evaluation of 11C-labeled (S)-nicotine, (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole, and (R,S)-1-methyl-2-(3-pyridyl)azetidine as nicotinic receptor ligands for positron emission tomography studies","volume":"71","author":"Sihver","year":"1998","journal-title":"J Neurochem."},{"key":"B268","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1021\/jm9507486","article-title":"Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol","volume":"39","author":"Jung","year":"1996","journal-title":"J Med Chem."},{"key":"B269","doi-asserted-by":"publisher","first-page":"672","DOI":"10.2967\/jnumed.113.132068","article-title":"18F-ASEM, a radiolabeled antagonist for imaging the \u03b17-nicotinic acetylcholine receptor with PET","volume":"55","author":"Horti","year":"2014","journal-title":"J Nucl Med."},{"key":"B270","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1101\/245118","article-title":"Brain PET imaging of \u03b17-nAChR with [18F]ASEM: reproducibility, occupancy, receptor density, and changes in schizophrenia","volume":"21","author":"Wong","year":"2018","journal-title":"Int J Neuropsychopharmacol."},{"key":"B271","doi-asserted-by":"publisher","first-page":"1536012117731258","DOI":"10.1177\/1536012117731258","article-title":"The search for a subtype-selective PET imaging agent for the GABAA receptor complex: evaluation of the radiotracer [11C]ADO in nonhuman primates","volume":"16","author":"Lin","year":"2017","journal-title":"Mol Imaging"},{"key":"B272","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/gbb.12321","article-title":"GABAA receptor subtype involvement in addictive behaviour","volume":"16","author":"Stephens","year":"2017","journal-title":"Genes Brain Behav"},{"key":"B273","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.nucmedbio.2013.06.004","article-title":"Novel fluorine-18 PET radiotracers based on flumazenil for GABAA imaging in the brain","volume":"40","author":"Rodnick","year":"2013","journal-title":"Nucl Med Biol."},{"key":"B274","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/0969-8051(94)00139-B","article-title":"Synthesis and PET imaging of the benzodiazepine receptor tracer [N-methyl-11C]iomazenil","volume":"22","author":"Baldwin","year":"1995","journal-title":"Nucl Med Biol."},{"key":"B275","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/jlcr.3008","article-title":"PET radioligands targeting the brain GABAA \/benzodiazepine receptor complex","volume":"56","author":"Andersson","year":"2013","journal-title":"J Label Compd Radiopharm."},{"key":"B276","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/0969-8051(94)00131-3","article-title":"Studies with [11C]alprazolam: an agonist for the benzodiazepine receptor","volume":"22","author":"Dobbs","year":"1995","journal-title":"Nucl Med Biol."},{"key":"B277","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/0022-3956(85)90080-9","article-title":"Imaging of [11C]-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography","volume":"19","author":"Persson","year":"1985","journal-title":"J Psychiatr Res"},{"key":"B278","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/0969-8051(93)90082-6","article-title":"Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites\u2013current status","volume":"20","author":"Pike","year":"1993","journal-title":"Nucl Med Biol."},{"key":"B279","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0014-2999(95)00633-8","article-title":"Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography","volume":"295","author":"Abadie","year":"1996","journal-title":"Eur J Pharmacol."},{"key":"B280","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/npp.2008.104","article-title":"Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects","volume":"34","author":"Frankle","year":"2009","journal-title":"Neuropsychopharmacology."},{"key":"B281","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/jnnp.57.7.797","article-title":"In vivo demonstration of altered benzodiazepine receptor density in patients with generalised epilepsy","volume":"57","author":"Savic","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B282","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.yebeh.2009.02.025","article-title":"PET and SPECT in epilepsy: a critical review","volume":"15","author":"la","year":"2009","journal-title":"Epilepsy Behav."},{"key":"B283","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S0140-6736(88)92468-3","article-title":"In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic FOCI","volume":"332","author":"Savic","year":"1988","journal-title":"Lancet"},{"key":"B284","doi-asserted-by":"publisher","first-page":"e1147","DOI":"10.1038\/tp.2017.124","article-title":"Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis","volume":"7","author":"Egerton","year":"2017","journal-title":"Transl Psychiatry"},{"key":"B285","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1161\/01.STR.0000134746.93535.9b","article-title":"Probability of cortical infarction predicted by flumazenil binding and diffusion-weighted imaging signal intensity","volume":"35","author":"Heiss","year":"2004","journal-title":"Stroke"},{"key":"B286","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00213-016-4506-4","article-title":"GABAA receptor occupancy by subtype selective GABAA\u03b12,3 modulators: PET studies in humans","volume":"234","author":"Jucaite","year":"2017","journal-title":"Psychopharmacology"},{"key":"B287","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1097\/RLU.0b013e318299610f","article-title":"Findings of 123I-iomazenil SPECT during and after stroke-like episodes in a patient with MELAS","volume":"39","author":"Taguchi","year":"2014","journal-title":"Clin Nucl Med"},{"key":"B288","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.eplepsyres.2013.03.008","article-title":"Statistical parametric mapping of interictal 123I-iomazenil SPECT in temporal lobe epilepsy surgery","volume":"106","author":"Fujitani","year":"2013","journal-title":"Epilepsy Res"},{"key":"B289","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fpsyt.2016.00016","article-title":"Altered SPECT (123)I-iomazenil binding in the cingulate cortex of children with anorexia nervosa","volume":"7","author":"Nagamitsu","year":"2016","journal-title":"Front Psychiatry."},{"key":"B290","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/00004647-200207000-00013","article-title":"Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography","volume":"22","author":"Lingford-Hughes","year":"2002","journal-title":"J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab."},{"key":"B291","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/syn.10169","article-title":"Visualization of alpha5 subunit of GABAA\/benzodiazepine receptor by 11C Ro15-4513 using positron emission tomography","volume":"47","author":"Maeda","year":"2003","journal-title":"Synap N Y N"},{"key":"B292","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0269881110379509","article-title":"A [11C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced \u03b15 benzodiazepine receptors in limbic regions","volume":"26","author":"Lingford-Hughes","year":"2012","journal-title":"J Psychopharmacol Oxf Engl."},{"key":"B293","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.schres.2007.10.014","article-title":"GABAA\/Benzodiazepine receptor binding in patients with schizophrenia using [11C]Ro15-4513, a radioligand with relatively high affinity for alpha5 subunit","volume":"99","author":"Asai","year":"2008","journal-title":"Schizophr Res."},{"key":"B294","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s00259-009-1066-4","article-title":"In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat","volume":"36","author":"Dedeurwaerdere","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B295","first-page":"181","article-title":"Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes","volume":"47","author":"Sieghart","year":"1995","journal-title":"Pharmacol Rev."},{"key":"B296","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/jcbfm.1994.56","article-title":"SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters","volume":"14","author":"Laruelle","year":"1994","journal-title":"J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab."},{"key":"B297","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.neuropharm.2012.04.008","article-title":"The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [11C]Ro15-4513 positron emission tomography study","volume":"68","author":"Mendez","year":"2013","journal-title":"Neuropharmacology"},{"key":"B298","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2967\/jnumed.112.107359","article-title":"18F-flumazenil: a \u03b3-aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsy","volume":"54","author":"Vivash","year":"2013","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B299","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1515\/raon-2016-0032","article-title":"(18)F-fluorodeoxyglucose and (18)F-flumazenil positron emission tomography in patients with refractory epilepsy","volume":"50","author":"Hodolic","year":"2016","journal-title":"Radiol Oncol."},{"key":"B300","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/med.20245","article-title":"5-HT radioligands for human brain imaging with PET and SPECT","volume":"33","author":"Paterson","year":"2013","journal-title":"Med Res Rev"},{"key":"B301","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.tips.2008.07.001","article-title":"A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory","volume":"29","author":"King","year":"2008","journal-title":"Trends Pharmacol Sci."},{"key":"B302","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.biopsych.2009.03.012","article-title":"The serotonin-1A receptor in anxiety disorders","volume":"66","author":"Akimova","year":"2009","journal-title":"Biol Psychiatry."},{"key":"B303","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1192\/bjp.bp.107.041186","article-title":"Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study","volume":"193","author":"Nash","year":"2008","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"B304","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.biopsych.2006.07.018","article-title":"Exaggerated 5-HT1A but normal 5-HT2A receptor activity in individuals ill with anorexia nervosa","volume":"61","author":"Bailer","year":"2007","journal-title":"Biol Psychiatry."},{"key":"B305","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.drudis.2007.07.008","article-title":"PET tracers for 5-HT(1A) receptors and uses thereof","volume":"12","author":"Kumar","year":"2007","journal-title":"Drug Discov Today"},{"key":"B306","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1212\/01.WNL.0000031424.51127.2B","article-title":"Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study","volume":"60","author":"Doder","year":"2003","journal-title":"Neurology."},{"key":"B307","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/brain\/awh109","article-title":"5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an [18F]MPPF-PET study","volume":"127","author":"Merlet","year":"2004","journal-title":"Brain J Neurol."},{"key":"B308","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1212\/01.wnl.0000271377.52421.4a","article-title":"Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment","volume":"69","author":"Truchot","year":"2007","journal-title":"Neurology."},{"key":"B309","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1468-2982.2008.01677.x","article-title":"Interictal Brain 5-HT1A receptors binding in migraine without Aura: a 18F-MPPF-PET study","volume":"28","author":"Lothe","year":"2008","journal-title":"Cephalalgia"},{"key":"B310","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/0333102410385581","article-title":"Brainstem changes in 5-HT1A receptor availability during migraine attack","volume":"31","author":"Demarquay","year":"2011","journal-title":"Cephalalgia"},{"key":"B311","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1093\/brain\/awn194","article-title":"Comorbidity between temporal lobe epilepsy and depression: a [18F]MPPF PET study","volume":"131","author":"Lothe","year":"2008","journal-title":"Brain J Neurol."},{"key":"B312","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0969-8051(00)00118-9","article-title":"PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635","volume":"27","author":"Carson","year":"2000","journal-title":"Nucl Med Biol."},{"key":"B313","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1212\/01.WNL.0000049930.93113.20","article-title":"PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy","volume":"60","author":"Toczek","year":"2003","journal-title":"Neurology."},{"key":"B314","first-page":"1128","article-title":"5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction","volume":"46","author":"Giovacchini","year":"2005","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B315","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.biopsych.2007.02.015","article-title":"5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression","volume":"62","author":"Hasler","year":"2007","journal-title":"Biol Psychiatry"},{"key":"B316","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1523\/JNEUROSCI.4921-03.2004","article-title":"Reduced serotonin type 1A receptor binding in panic disorder","volume":"24","author":"Neumeister","year":"2004","journal-title":"J Neurosci Off J Soc Neurosci."},{"key":"B317","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.162.2.383","article-title":"No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder","volume":"162","author":"Bonne","year":"2005","journal-title":"Am J Psychiatry."},{"key":"B318","doi-asserted-by":"publisher","first-page":"e0121342","DOI":"10.1371\/journal.pone.0121342","article-title":"18F-Mefway PET imaging of serotonin 1A receptors in humans: a comparison with 18F-FCWAY","volume":"10","author":"Choi","year":"2015","journal-title":"PLoS ONE."},{"key":"B319","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.2967\/jnumed.110.076257","article-title":"In vivo quantification of human serotonin 1A receptor using 11C-CUMI-101, an agonist PET radiotracer","volume":"51","author":"Milak","year":"2010","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B320","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1192\/bjp.173.3.236","article-title":"5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150","volume":"173","author":"Travis","year":"1998","journal-title":"Br J Psychiatry J Ment Sci."},{"key":"B321","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s002130100761","article-title":"In vivo 5-HT2A receptor blockade by quetiapine: an R91150 single photon emission tomography study","volume":"157","author":"Jones","year":"2001","journal-title":"Psychopharmacology"},{"key":"B322","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0197-4580(02)00137-9","article-title":"Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings","volume":"24","author":"Versijpt","year":"2003","journal-title":"Neurobiol Aging"},{"key":"B323","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0165-0327(01)00482-7","article-title":"Prefrontal 5-HT2a receptor binding index, hopelessness and personality characteristics in attempted suicide","volume":"74","author":"van Heeringen","year":"2003","journal-title":"J Affect Disord."},{"key":"B324","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jpsychires.2005.04.002","article-title":"Differences of cortical 5-HT2A receptor binding index with SPECT in subtypes of anorexia nervosa: relationship with personality traits?","volume":"41","author":"Goethals","year":"2007","journal-title":"J Psychiatr Res."},{"key":"B325","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/sj.npp.1300555","article-title":"Decreased hippocampal 5-HT(2A) receptor binding in older depressed patients using [18F]altanserin positron emission tomography","volume":"29","author":"Sheline","year":"2004","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"B326","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1176\/ajp.156.12.1871","article-title":"PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders","volume":"156","author":"Meltzer","year":"1999","journal-title":"Am J Psychiatry."},{"key":"B327","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1017\/S1461145706006559","article-title":"Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome","volume":"10","author":"Haugb\u00f8l","year":"2007","journal-title":"Int J Neuropsychopharmacol."},{"key":"B328","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/sj.npp.1301656","article-title":"Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients","volume":"33","author":"Erritzoe","year":"2008","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol."},{"key":"B329","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0006-3223(02)01378-1","article-title":"Reduced 5-HT2A receptor binding after recovery from anorexia nervosa","volume":"52","author":"Frank","year":"2002","journal-title":"Biol Psychiatry"},{"key":"B330","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1017\/S1461145705005055","article-title":"Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei","volume":"8","author":"Adams","year":"2005","journal-title":"Int J Neuropsychopharmacol."},{"key":"B331","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00259-005-1912-y","article-title":"Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study","volume":"32","author":"Erlandsson","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B332","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00213-006-0486-0","article-title":"In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram","volume":"188","author":"Klein","year":"2006","journal-title":"Psychopharmacology"},{"key":"B333","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00702-005-0429-7","article-title":"Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM","volume":"113","author":"Herold","year":"2006","journal-title":"J Neural Transm"},{"key":"B334","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1176\/appi.ajp.158.11.1843","article-title":"Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study","volume":"158","author":"Meyer","year":"2001","journal-title":"Am J Psychiatry"},{"key":"B335","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.biopsych.2005.08.010","article-title":"Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography","volume":"59","author":"Parsey","year":"2006","journal-title":"Biol Psychiatry."},{"key":"B336","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00213-007-0806-z","article-title":"Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography","volume":"193","author":"Voineskos","year":"2007","journal-title":"Psychopharmacology"},{"key":"B337","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1017\/S1461145706007486","article-title":"PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram","volume":"10","author":"Lundberg","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"B338","first-page":"973","article-title":"123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study","volume":"46","author":"Newberg","year":"2005","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B339","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00415-006-0444-0","article-title":"Increased serotonin transporter availability in the brainstem of migraineurs","volume":"254","author":"Schuh-Hofer","year":"2007","journal-title":"J Neurol"},{"key":"B340","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1176\/appi.ajp.2007.06111933","article-title":"5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB","volume":"164","author":"Bhagwagar","year":"2007","journal-title":"Am J Psychiatry."},{"key":"B341","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.biopsych.2005.02.028","article-title":"Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB","volume":"57","author":"Frankle","year":"2005","journal-title":"Biol Psychiatry."},{"key":"B342","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00702-007-0785-6","article-title":"Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity \u2013 a [11C]DASB PET study","volume":"114","author":"Reimold","year":"2007","journal-title":"J Neural Transm"},{"key":"B343","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1530-0277.2006.00261.x","article-title":"PET [11C]DASB imaging of serotonin transporters in patients with alcoholism","volume":"31","author":"Brown","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"B344","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.biopsych.2006.05.005","article-title":"Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography","volume":"60","author":"Cannon","year":"2006","journal-title":"Biol Psychiatry."},{"key":"B345","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.neuroimage.2008.12.001","article-title":"The personality trait openness is related to cerebral 5-HTT levels","volume":"45","author":"Kalbitzer","year":"2009","journal-title":"NeuroImage"},{"key":"B346","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.biopsych.2009.11.027","article-title":"Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes","volume":"67","author":"Kalbitzer","year":"2010","journal-title":"Biol Psychiatry"},{"key":"B347","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.apradiso.2012.06.005","article-title":"Synthesis and comparison of 4-[18F]F-ADAM, 2-[18F]F-ADAM, N-Desmethyl-4-[18F]F-ADAM and [18F]F-AFM as serotonin transporter imaging agents","volume":"70","author":"Huang","year":"2012","journal-title":"Appl Radiat Isot"},{"key":"B348","doi-asserted-by":"publisher","first-page":"pyu120","DOI":"10.1093\/ijnp\/pyu120","article-title":"Disproportionate reduction of serotonin transporter may predict the response and adherence to antidepressants in patients with major depressive disorder: a positron emission tomography study with 4-[18F]-ADAM","volume":"18","author":"Yeh","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"B349","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.biopsych.2005.05.006","article-title":"Brain serotonin1A receptor binding in major depression is related to psychic and somatic anxiety","volume":"58","author":"Sullivan","year":"2005","journal-title":"Biol Psychiatry."},{"key":"B350","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.pscychresns.2009.03.007","article-title":"Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [18F]deuteroaltanserin and PET","volume":"173","author":"Santhosh","year":"2009","journal-title":"Psychiatry Res Neuroimaging"},{"key":"B351","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1176\/ajp.2006.163.9.1580","article-title":"Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907","volume":"163","author":"Bhagwagar","year":"2006","journal-title":"Am J Psychiatry."},{"key":"B352","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.neuroimage.2008.04.233","article-title":"In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder","volume":"42","author":"Perani","year":"2008","journal-title":"NeuroImage"},{"key":"B353","first-page":"1697","article-title":"Synthesis and biologic evaluation of a novel serotonin 5-HT1A receptor radioligand, 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primate","volume":"47","author":"Saigal","year":"2006","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B354","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0969-8051(02)00316-5","article-title":"In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography","volume":"29","author":"Wilson","year":"2002","journal-title":"Nucl Med Biol."},{"key":"B355","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/mp.2012.78","article-title":"Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study","volume":"17","author":"Selvaraj","year":"2012","journal-title":"Mol Psychiatry"},{"key":"B356","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/syn.20443","article-title":"Neuroimaging of the serotonin reuptake site requires high-affinity ligands","volume":"61","author":"Elfving","year":"2007","journal-title":"Synapse."},{"key":"B357","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0883-2897(88)90018-9","article-title":"Synthesis, affinity and specificity of 18F-setoperone, a potential ligand for in-vivo imaging of cortical serotonin receptors","volume":"15","author":"Maziere","year":"1988","journal-title":"Int J Rad Appl Instrum B"},{"key":"B358","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/brain\/116.3.497","article-title":"Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone","volume":"116","author":"Blin","year":"1993","journal-title":"Brain J Neurol."},{"key":"B359","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1046\/j.1468-2982.1995.015002104.x","article-title":"5HT2 receptors in cerebral cortex of migraineurs studied using PET and 18F-fluorosetoperone","volume":"15","author":"Chabriat","year":"1995","journal-title":"Cephalalgia Int J Headache."},{"key":"B360","first-page":"1976","article-title":"Post-stroke changes in cortical 5-HT2 serotonergic receptors","volume":"37","author":"V\u00e9ra","year":"1996","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B361","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s002130050377","article-title":"Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors","volume":"133","author":"Massou","year":"1997","journal-title":"Psychopharmacology"},{"key":"B362","first-page":"1890","article-title":"N,N-Dimethyl-2-(2-Amino-4-18F-Fluorophenylthio)-Benzylamine (4-18F-ADAM): an improved PET radioligand for serotonin transporters","volume":"44","author":"Shiue","year":"2003","journal-title":"J Nucl Med."},{"key":"B363","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.2967\/jnumed.113.136515","article-title":"Molecular imaging insights into neurodegeneration: focus on \u03b1-synuclein radiotracers","volume":"55","author":"Shah","year":"2014","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"B364","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1126\/science.1195227","article-title":"Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro","volume":"329","author":"Burr\u00e9","year":"2010","journal-title":"Science"},{"key":"B365","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1096\/fj.03-0098fje","article-title":"Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma","volume":"17","author":"El-Agnaf","year":"2003","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"B366","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1523\/JNEUROSCI.0692-05.2005","article-title":"Intravesicular localization and exocytosis of alpha-synuclein and its aggregates","volume":"25","author":"Lee","year":"2005","journal-title":"J Neurosci Off J Soc Neurosci."},{"key":"B367","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","article-title":"Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria","volume":"8","author":"Dickson","year":"2009","journal-title":"Lancet Neurol."},{"key":"B368","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/mds.26547","article-title":"Imaging synucleinopathies","volume":"31","author":"Brooks","year":"2016","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"B369","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/brain\/awn349","article-title":"Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies","volume":"132","author":"Paleologou","year":"2009","journal-title":"Brain J Neurol."},{"key":"B370","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ymgme.2011.06.008","article-title":"Aggregation of \u03b1-synuclein in brain samples from subjects with glucocerebrosidase mutations","volume":"104","author":"Choi","year":"2011","journal-title":"Mol Genet Metab."},{"key":"B371","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","article-title":"Pathologic accumulation of \u03b1-synuclein and A\u03b2 in parkinson disease patients with dementia","volume":"69","author":"Kotzbauer","year":"2012","journal-title":"Arch Neurol."},{"key":"B372","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/jnc.12226","article-title":"Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies","volume":"125","author":"Schildknecht","year":"2013","journal-title":"J Neurochem"},{"key":"B373","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00401-005-1044-2","article-title":"Silver stainings distinguish Lewy bodies and glial cytoplasmic inclusions: comparison between Gallyas-Braak and Campbell-Switzer methods","volume":"110","author":"Uchihara","year":"2005","journal-title":"Acta Neuropathol"},{"key":"B374","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"J Biol Chem."},{"key":"B375","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.neuroimage.2007.09.072","article-title":"[11C]PIB binding in Parkinson's disease dementia","volume":"39","author":"Maetzler","year":"2008","journal-title":"NeuroImage"},{"key":"B376","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejphar.2009.06.042","article-title":"In vitro characterisation of BF227 binding to alpha-synuclein\/Lewy bodies","volume":"617","author":"Fodero-Tavoletti","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"B377","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/brain\/awq091","article-title":"In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy","volume":"133","author":"Kikuchi","year":"2010","journal-title":"Brain J Neurol."},{"key":"B378","doi-asserted-by":"publisher","first-page":"9165458","DOI":"10.1155\/2018\/9165458","article-title":"Amyloid-beta radiotracer [18F]BF-227 does not bind to cytoplasmic glial inclusions of postmortem multiple system atrophy brain tissue","volume":"2018","author":"Verdurand","year":"2018","journal-title":"Contrast Media Mol Imaging."},{"key":"B379","doi-asserted-by":"publisher","first-page":"e55031","DOI":"10.1371\/journal.pone.0055031","article-title":"Binding of the radioligand SIL23 to \u03b1-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent","volume":"8","author":"Bagchi","year":"2013","journal-title":"PLoS ONE"},{"key":"B380","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1021\/acs.molpharmaceut.8b00229","article-title":"In silico, in vitro, and in vivo evaluation of new candidates for \u03b1-synuclein PET imaging","volume":"15","author":"Verdurand","year":"2018","journal-title":"Mol Pharm"},{"key":"B381","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/j.1471-4159.2008.05245.x","article-title":"In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain","volume":"105","author":"Ye","year":"2008","journal-title":"J Neurochem."},{"key":"B382","doi-asserted-by":"publisher","first-page":"10365","DOI":"10.1523\/JNEUROSCI.0630-07.2007","article-title":"In vitro characterization of pittsburgh compound-B binding to lewy bodies","volume":"27","author":"Fodero-Tavoletti","year":"2007","journal-title":"J Neurosci."},{"key":"B383","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3233\/JAD-2006-9S347","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop","volume":"9","author":"McKeith","year":"2006","journal-title":"J Alzheimers Dis JAD"},{"key":"B384","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0022-510X(98)00304-9","article-title":"Consensus statement on the diagnosis of multiple system atrophy","volume":"163","author":"Gilman","year":"1999","journal-title":"J Neurol Sci."},{"key":"B385","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00002826-200101000-00008","article-title":"A revised excitotoxic hypothesis of schizophrenia: therapeutic implications","volume":"24","author":"Deutsch","year":"2001","journal-title":"Clin Neuropharmacol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00268\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:12:22Z","timestamp":1665101542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00268\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":385,"alternative-id":["10.3389\/fmed.2019.00268"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2019.00268","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,27]]},"article-number":"268"}}